The Beat Executive Series: Revolutionizing Disease Advancement Through Science and Tech with Mike Montello
About Mike Montello:
Mike Montello serves as the Senior Vice President, R&D Digital and Tech at GSK, a pharmaceutical company that ranks among the top ten globally and generates over $36 billion in revenue. Oncology, immunology, respiratory disorders, HIV, and infectious illnesses are its strong therapeutic domains. Mike is a sponsor of multiple aspects of GSK's overall digital transformation, including the company's transition to a product-centric structure, its strategic alliances with IT firms, and its digital training initiatives. Building diverse teams and encouraging inclusive leaders are two things that particularly inspire and excite him personally. He gets his energy from speeding innovation through culture. His other main concern is giving GSK's AI machine learning engineers the best quality data in the safest manner possible.
Over his career, Mike has worked to improve healthcare via the use of digital, data, and analytics technologies. Mike held the position of CIO at Quintiles prior to the company's 2018 rebranding as IQVIA. He was in charge of the technological platforms that allowed clinical trials to take place in over 100 nations. Along with leading the product teams that developed the next generation of clinical development data and analytics capabilities, decentralized trial platforms, and supported multiple tech acquisitions, Mike also directed the company's R&D technology strategy following the merger with IMS and Quintiles. In addition to spending several years in IT leadership positions at Shire Pharmaceuticals, Mike spent twelve years working as a management consultant at Accenture, where he developed his basic understanding of biopharmaceuticals and technology.
Mike has a mechanical engineering degree and graduated from London Business School with an executive MBA.
Things You’ll Learn:
- Every pharmaceutical company needs transformation and acceleration.
- GSK is using AI to identify patients who are most likely to respond favorably to medicines and vaccines by leveraging appropriate data.
- In the pharma sector, there is a constant need to accelerate clinical trials, drug discovery, and the commercialization process.
- Large language models and AI will help us a lot with mundane activities.
- We have to balance the benefits of AI with making sure we're doing things extremely responsibly.
- It's less about the technology and more about serving people with that technology.
Resources: